

---

## Hikma Participates in 'World Economic Forum on the Middle East and North Africa' at Dead Sea, Jordan

---

Amman, Jordan, 8 April 2019 - [Hikma Pharmaceuticals PLC](#) (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), the multinational generic pharmaceutical company, participated in the World Economic Forum Middle East and North Africa (MENA), which took place on 6 and 7 April at the King Hussein bin Talal Convention Centre, Dead Sea, Jordan. The event focused on how the MENA region will achieve socio-economic progress in the age of the Fourth Industrial Revolution driven by new technology and data.

Attended by Their Majesties King Abdullah II and Queen Rania Al Abdullah, the event convened over 1,000 key government, business and civil society leaders from 50 countries to prompt collaboration and action-oriented dialogue on the most pressing challenges facing the MENA. Attendees were challenged to consider how the region can make progress on the regional and national agendas for inclusive economic growth, social advancement and sustainable development across diverse sectors.

Mazen Darwazah, Executive Chairman and President of MENA, spoke on a panel entitled 'New Platforms for Healthcare' - discussing the shift of the healthcare industry towards digitization. The panel explored topics including investment into health tech, the changing doctor-patient relationship, the implications of real-world data, as well as access and affordability, among others.

Commenting on Hikma's involvement, Darwazah stated, "The MENA region is one of the world's most rapidly transforming regions, demographically, socially, politically, economically and environmentally, with some estimates that our population will exceed that of China by the end of the century. It is essential we work together at forums like this to ensure that we are able to help how industry organizations and communities across the MENA interact and impact one another to meet these challenges and opportunities."

-Ends-

### **About Hikma**

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,400 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: [www.hikma.com](http://www.hikma.com)



**Enquiries**  
**Hikma Pharmaceuticals**

Dana Alhusseini  
Email: Dalhusseini@hikma.com  
Tel: +962 6 580 2900

This press release has been distributed by **Bidaya Corporate Communications** on behalf of Hikma Pharmaceuticals.

Tel: +962 6 585 4002/6  
Fax: +962 6 585 3001  
P.O. Box: 930391, Amman 11193, Jordan  
Email: media@bidayacorp.com